Abstract:Background: Accumulating experimental data supports the capacity of natural compounds to intervene in complicated molecular pathways underlying the pathogenesis of certain human morbidities. Among them, diabetes is now a world’s epidemic associated with increased risk of death; thus, the detection of novel anti-diabetic agents and/or adjuvants is of vital importance. Alkaloids represent a diverse group of natural products with a range of therapeutic properties; during the last 20 years, published research on their anti-diabetic capacity has been tremendously increased. Purpose: To discuss current concepts on the anti-diabetic impact of certain alkaloids, with special reference to their molecular targets throughout the insulin-signaling pathway. Methodology: Upon in-depth search in the SCOPUS and PUBMED databases, the literature on alkaloids with insulin secretion/sensitization properties was critically reviewed. Results: In-vitro and in-vivo evidence supports the effect of berberine, trigonelline, piperine, oxymatrine, vindoneline, evodiamine and neferine on insulin-signaling and related cascades in beta-cells, myocytes, adipocytes, hepatocytes and other cells. Associated receptors, kinases, hormones and cytokines, are affected in terms of gene transcription, protein expression, activity and/or phosphorylation. Pathophysiological processes associated with insulin resistance, beta-cell failure, oxidative stress and inflammation, as well as clinical phenotype are also influenced. Discussion: Growing evidence suggests the ability of specific alkaloids to intervene in the insulin-signal transduction pathway, reverse molecular defects resulting in insulin resistance and glucose intolerance and improve disease complications, in-vitro and in-vivo. Future indepth molecular studies are expected to elucidate their exact mechanism of action, while large clinical trials are urgently needed to assess their potential as anti-diabetic agents.

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones

Targeting Insulin-Degrading Enzyme in Insulin Clearance

Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases

Stabilized Β-Hairpin Peptide Inhibits Insulin Degrading Enzyme.

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review

Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display

Novel DPP-4 Inhibitors Against Diabetes

Progress on Glucosidase Inhibitors

Insulin-degrading enzyme regulates insulin-directed cellular autoimmunity in murine type 1 diabetes

Novel idebenone analogs block Shc’s access to insulin receptor to improve insulin sensitivity

Unlocking potential diabetes therapeutics: Insights into alpha-glucosidase inhibition

New anti-diabetic agents-DPP-4 inhibitors: Viewing the advance of treatment for T2DM from pancreatic α-cells

Natural Alkaloids Intervening the Insulin Pathway: New Hopes for Anti-Diabetic Agents?

Discovery of the selective and nanomolar inhibitor of DPP-4 more potent than sitagliptin by structure-guided rational design

Identifying Human PTP1B Enzyme Inhibitors from Marine Natural Products: Perspectives for Developing of Novel Insulin-Mimetic Drugs

Discovery of Novel Anti-Diabetic Drugs by Targeting Lipid Metabolism

Identification of Electrostatic Hotspots at the Binding Interface of Amylin and InsulinDegrading Enzyme: A Structural and Biophysical Investigation

Non-peptidyl small molecule, adenosine, 5'-Se-methyl-5'-seleno-, 2',3'-diacetate, activates insulin receptor and attenuates hyperglycemia in type 2 diabetic Leprdb/db mice

Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists